Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24643163 | 0.75 | DPP4 (0.37) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL6124708 | 0.74 | DPP4 (0.46) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL13167986 | 0.73 | ALDH1A1 (0.44) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL12852762 | 0.73 | ALDH1A1 (0.44) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL10190250 | 0.73 | ALDH1A1 (0.44) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL6127933 | 0.72 | DPP4 (0.45) | DPP4SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL600921 | 0.71 | ALDH1A1 (0.43) | DPP4SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL600920 | 0.71 | ALDH1A1 (0.43) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL11913043 | 0.71 | DPP4 (0.36) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL20959518 | 0.70 | DPP4 (0.36) | DPP4SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858835-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| CN-109789143-A | Antiproliferative based on pyrimidine | G1治疗公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | DPP4 3279/4885SLC6A4 3172/4885SLC6A3 3566/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | DPP4 3279/4885SLC6A4 3172/4885SLC6A3 3566/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | DPP4 1556/4885SLC6A4 3075/4885SLC6A3 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.